Authors

  • Alimov S.M., Tursunov D.Kh., Asadullayev M.M.

Keywords:

metabolic syndrome, atherosclerosis, insulin resistance, dyslipidemia, oxidative stress, endothelial dysfunction, inflammasome.

References

Brownlee M. Biochemistry of hyperglycemia // Nature. – 2023.

Datta S. Leptin and CVD // Biomolecules. – 2023.

DeFronzo R.A. Insulin signaling defects // Diabetes. – 2022.

Duewell P. NLRP3 and cholesterol crystals // Nature. – 2022.

Esmon C.T. Inflammation and thrombosis // Blood. – 2021.

Ferrannini E. Insulin resistance and CVD // Eurор. Heart J. – 2022.

Förstermann U. Oxidative stress in endothelium // Eurор. Heart J. – 2022.

Förstermann U., Sessa W.C. NO signaling. // Eurор. Heart J. – 2021.

Furman D. Metaflammation // Nat. Med. – 2023.

Gimbrone M.A. Endothelial dysfunction // J. Clin. Invest. – 2021.16

Grundy S.M. Metabolic syndrome update // Circulation. – 2021.

Hirano T. Small dense ZPLP // J. Atheroscler. Thromb. – 2022.

Hotamisligil G.S. Inflammation and metabolic disorders // Nature. – 2023.

Libby P. Inflammation and atherosclerosis // Circ. Res. – 2021.

Libby P. Plaque instability // Eurор. Heart J. – 2023.

Liberale L. Adiponectin and risk // Atherosclerosis. – 2024.

Madamanchi N.R. ROS and atherosclerosis // Antioxid. Redox Signal. – 2022.

Nordestgaard B.G. Triglycerides and risk // Eurор. Heart J. – 2021.

Ouchi N. Adipose inflammation // Nat. Rev. Immunol. – 2021.

Packard C.J. Atherogenic lipoproteins // Curr. Opin. Lipidol. – 2023.

Rader D.J. ApoB and residual risk // Circulation. – 2022.

Ridker P.M. hsCRP and CVD risk // N.E.J.M. – 2021.

Sattar N., McGuire D.K. Metabolic risk and ASCVD // Lancet. – 2021.

Schmidt A.M. AGE-RAGE signaling // Nat. Rev. Endocrinol. – 2021.

Tabas I. Foam cell formation // Nat. Rev. Cardiol. – 2021.

Tabas I., Bornfeldt K.E. Macrophage biology in atherosclerosis // Nat. Rev. Immunol. – 2022.

Tall A.R. Inflammasomes in atherosclerosis // Circ. Res. – 2023.

Vlassara H. AGEs and vascular injury // J.A.C.C. – 2022.